ALKERMES | ALKS - 贸易债权人

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.91B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	贸易债权人	更改		日
AbbVie	USD 3.59B		28.65B	2025-12
Acadia Pharmaceuticals	USD 44.57M		32.32M	2026-06
ALKERMES	USD 142.86M		40.5M	2026-06
Amgen	USD 2.86B		16.65B	2026-06
Biogen	USD 403.9M		45.4M	2026-06
BioMarin Pharmaceutical	USD 913.67M		120.52M	2026-06
Bristol-Myers Squibb	USD 4.16B		76M	2026-06
Coherus Biosciences	USD 13.17M		1.69M	2026-06
Eli Lilly	USD 6.11B		1.08B	2026-06
Gilead Sciences	USD 645M		70M	2026-03
Heron Therapeutics	USD 11.64M		2.67M	2026-06
Ionis Pharmaceuticals	USD 47.7M		21.67M	2026-06
J&J	USD 9.22B		1.24B	2026-06
Malin Corporation	EUR 700K		200K	2024-12
Merck	USD 3.83B		36M	2026-06
Minerva Neurosciences	USD 640K		305K	2025-12
Nektar Therapeutics	USD 10.03M		744K	2026-03
Neurocrine Biosciences	USD 691.3M		145.8M	2026-03
Otsuka Holdings	JPY 216.64B		20.6B	2026-06
Ovoca Bio	EUR 1.3M		1.11M	2025-12
Pfizer	USD 4.58B		75M	2026-06
Regeneron Pharmaceuticals	USD 1.16B		132.2M	2026-06
Vertex Pharmaceuticals	USD 3.61B		135M	2026-06